Advertisement

Investigational New Drugs

, Volume 10, Issue 4, pp 323–325 | Cite as

Phase II study of gemcitabine in advanced colorectal adenocarcinoma

  • Dennis F. MooreJr.
  • Richard Pazdur
  • Karen Daugherty
  • Peter Tarassoff
  • James L. Abbruzzese
Phase II Clinical Trials

Summary

A phase II trial of gemcitabine (difluorodeoxycytidine) was conducted in 14 patients with advanced colorectal adenocarcinoma. Gemcitabine was administered intravenously over 30 minutes at weekly intervals for 3 consecutive weeks each month. The starting dose was 800 mg/m2, with dose escalation as tolerated. No complete or partial response were observed. Ten patients experienced progressive disease while on therapy. Toxic effects were primarily hematologic in nature. Grade 3 toxicities included leukopenia (one patient at 1000 mg/m2), granulocytopenia (two patients at 800 mg/m2), anemia (two patients at 800 mg/m2), and myalgia (one patient at 800 mg/m2). No grade 4 toxic effects or treatment-associated deaths were observed. Gemcitabine, at the doses and schedule used in this study, did not demonstrate activity against advanced colorectal adenocarcinoma.

Key words

difluorodeoxycytidine gemcitabine colorectal adenocarcinoma carcinoma 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Heidelberg C, Chandhari NK, Danneberg P, (et al.): Fluorinated pyrmidine: a new class of tumor-inhibiting compounds. Nature 179:663–666, 1957Google Scholar
  2. 2.
    Abbruzzese JL, Levin B: Treatment of advanced colorectal cancer. New Perspectives in Large Bowel Cancer. The Hematology/Oncology Clinics of North America 3:135–153, 1989Google Scholar
  3. 3.
    Ehrlichman C, Fine S, Wong A (et al.): A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 6:469–475, 1988Google Scholar
  4. 4.
    Petrelli N, Douglass HO, Herrera L, Russell D, Stablein DM, Bruckner HW, Mayer RJ, Schinella R, Green MD, Muggia FM: The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J Clin Oncol 7:1419–1426, 1989Google Scholar
  5. 5.
    Poon MA, O'Connell MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK, Krook JE, Mailliard JA, Laurie JA, Tschetter LK: Biochemical modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J Clin Oncol 7:1419–1426, 1989Google Scholar
  6. 6.
    O'Dwyer PJ, Paul AR, Walczak J, Weiner LM, Litwin, S, Comis RL: Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer. J Clin Oncol 8:1497–1503, 1990Google Scholar
  7. 7.
    Pazdur R, Anjani JA, Patt YZ, Winn R, Jackson D, Sheperd B, DuBrow R, Campos L, Quaraishi M, Faintuch J, Abbruzzese JL, Gutterman J, Levin B: Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma. J Clin Oncol 8:2027–2031, 1990Google Scholar
  8. 8.
    Wadler S, Lembersky B, Atkins M, Kirkwood J, Petrelli N: Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: An Eastern Cooperative Oncology Group study. J Clin Oncol 9:1806–1810, 1991Google Scholar
  9. 9.
    Einhorn LH: Improvements in fluorouracil chemotherapy? J Clin Oncol 7:1377–1379, 1989Google Scholar
  10. 10.
    Hertel LW, Kroin JS, Misner JW, (et al): Synthesis of 2-deoxy-2′, 2′-difluoro-D-ribose and 2-deoxy-2′, 2′-difluoro-D-ribofuranosyl nucleosides. J Org Chem 53: 2406–2409, 1988Google Scholar
  11. 11.
    Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, Grindey GB: Evaluation of the antitumor activity of gemcitabine (2′, 2′-difluoro-2′-deoxycytine). Cancer Res 50:4417–4422, 1990Google Scholar
  12. 12.
    Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarasshoff P, Plunkett W: A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9:491–498, 1991Google Scholar
  13. 13.
    Miller AB, Hoogstraten B, Staquet M (et al): Reporting results of cancer treatment. Cancer 47:207–214, 1981Google Scholar
  14. 14.
    Ajani JA, Abbruzzese JL, Goudeau P, Faintuch J, Yeomans A, Boman B, Levin B: Ifosfamide and mesna: marginally active in patients with advanced carcinoma of the pancreas. J Clin Oncol 6:1703–1707, 1988Google Scholar
  15. 15.
    Heinemann V, Hertel LW, Grindey GB, Plunkett W: Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodexoycytidine and 1-(beta)-D-arabinofuranosylcytosine. Cancer Res 48:4024–4031, 1988Google Scholar
  16. 16.
    Anderson H, Lund B, Hanse HH, (et al): Phase II study of gemcitabine in non-small cell lung cancer (Abstract). Proc American Society Clinical Oncology 10: 247, 1991Google Scholar
  17. 17.
    Casper ES, Green MR, Brown TD, (et al.): Phase II trial of Gemcitabine (2′,2′-difluorodeoxycytidine) in patients with pancreatic cancer (Abstract). Proc American Society Clinical Oncology 10:143, 1991Google Scholar
  18. 18.
    Grunewald R, Abbruzzese JL, Tarasoff P, Plunkett W: Saturation of 2′,2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 27: 258–262, 1991Google Scholar
  19. 19.
    Grunewald R, Kantarjian H, Keating MJ, (et al): Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (gemcitabine) administration in leukemia. Cancer Res 50:6823–6826, 1990Google Scholar
  20. 20.
    Grunewald R, Kantarjian H, Du M, Faucher K, Tarassoff P, Plunkett W: Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol 10:406–413, 1992Google Scholar
  21. 21.
    Raber M, Abbruzzese JL, Lippman S, Fossella F, Gravel D, Plunkett W, Tarassoff P: Phase I/II studies of escalated doses of gemcitabine in patients with solid tumors. 7th EORTC/NCI: Symposium on New Drugs in Cancer Therapy, Amsterdam, The Netherlands Annals of Oncology 3:135, 1992 (Supplement 1)Google Scholar

Copyright information

© Kluwer Academic Publishers 1992

Authors and Affiliations

  • Dennis F. MooreJr.
    • 1
  • Richard Pazdur
    • 1
  • Karen Daugherty
    • 1
  • Peter Tarassoff
    • 1
  • James L. Abbruzzese
    • 1
  1. 1.Section of Gastrointestinal OncologyUniversity of Texas, M.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations